Dr. Geynisman on Patient Preferences for Treatment of RCC

Daniel M. Geynisman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses patient preferences for the treatment of renal cell carcinoma (RCC).

According to Geynisman, patients are very motivated and interested in participating in clinical trials of immunotherapy.

Patients can derive tremendous benefit for a long time from immunotherapy, which is very different from most treatments, states Geynisman.